TY - JOUR
T1 - Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms
AU - Lee, Hwa Kyung
AU - Moon, Joon Kwan
AU - Chang, Chul Hee
AU - Choi, Hoon
AU - Park, Hee Won
AU - Park, Byeoung Soo
AU - Lee, Hye Suk
AU - Hwang, Eul Chul
AU - Lee, Young Deuk
AU - Liu, Kwang Hyeon
AU - Kim, Jeong Han
PY - 2006
Y1 - 2006
N2 - Endosulfan (6,7,8,9,10,10-hexachloro-1,5,5a,6,9,9a-hexahydro-6,9-methano-2, 3,4-benzo(e)dioxathiepin-3-oxide) is a broad-spectrum chlorinated cyclodiene insecticide. This study was performed to elucidate the stereoselective metabolism of endosulfan in human liver microsomes and to characterize the cytochrome P450 (P450) enzymes that are involved in the metabolism of endosulfan. Human liver microsomal incubation of endosulfan in the presence of NADPH resulted in the formation of the toxic metabolite, endosulfan sulfate. The intrinsic clearances (CLint) of endosulfan sulfate from β-endosulfan were 3.5-fold higher than those from α-endosulfan, suggesting that β-endosulfan would be cleared more rapidly than α-endosulfan. Correlation analysis between the known P450 enzyme activities and the rate of the formation of endosulfan sulfate in the 14 human liver microsomes showed that α-endosulfan metabolism is significantly correlated with CYP2B6-mediated bupropion hydroxylation and CYP3A-mediated midazolam hydroxylation, and that β-endosulfan metabolism is correlated with CYP3A activity. The P450 isoform-selective inhibition study in human liver microsomes and the incubation study of cDNA-expressed enzymes also demonstrated that the stereoselective sulfonation of α-endosulfan is mediated by CYP2B6, CYP3A4, and CYP3A5, and that that of β-endosulfan is transformed by CYP3A4 and CYP3A5. The total CLint values of endosulfan sulfate formation catalyzed by CYP3A4 and CYP3A5 were consistently higher for β-endosulfan than for the α-form (CLint of 0.67 versus 10.46 μl/min/pmol P450, respectively). CYP2B6 enantioselectively metabolizes α-endosulfan, but not β-endosulfan. These findings suggest that the CYP2B6 and CYP3A enzymes are major enzymes contributing to the stereoselective disposition of endosulfan.
AB - Endosulfan (6,7,8,9,10,10-hexachloro-1,5,5a,6,9,9a-hexahydro-6,9-methano-2, 3,4-benzo(e)dioxathiepin-3-oxide) is a broad-spectrum chlorinated cyclodiene insecticide. This study was performed to elucidate the stereoselective metabolism of endosulfan in human liver microsomes and to characterize the cytochrome P450 (P450) enzymes that are involved in the metabolism of endosulfan. Human liver microsomal incubation of endosulfan in the presence of NADPH resulted in the formation of the toxic metabolite, endosulfan sulfate. The intrinsic clearances (CLint) of endosulfan sulfate from β-endosulfan were 3.5-fold higher than those from α-endosulfan, suggesting that β-endosulfan would be cleared more rapidly than α-endosulfan. Correlation analysis between the known P450 enzyme activities and the rate of the formation of endosulfan sulfate in the 14 human liver microsomes showed that α-endosulfan metabolism is significantly correlated with CYP2B6-mediated bupropion hydroxylation and CYP3A-mediated midazolam hydroxylation, and that β-endosulfan metabolism is correlated with CYP3A activity. The P450 isoform-selective inhibition study in human liver microsomes and the incubation study of cDNA-expressed enzymes also demonstrated that the stereoselective sulfonation of α-endosulfan is mediated by CYP2B6, CYP3A4, and CYP3A5, and that that of β-endosulfan is transformed by CYP3A4 and CYP3A5. The total CLint values of endosulfan sulfate formation catalyzed by CYP3A4 and CYP3A5 were consistently higher for β-endosulfan than for the α-form (CLint of 0.67 versus 10.46 μl/min/pmol P450, respectively). CYP2B6 enantioselectively metabolizes α-endosulfan, but not β-endosulfan. These findings suggest that the CYP2B6 and CYP3A enzymes are major enzymes contributing to the stereoselective disposition of endosulfan.
UR - http://www.scopus.com/inward/record.url?scp=33745255092&partnerID=8YFLogxK
U2 - 10.1124/dmd.105.009134
DO - 10.1124/dmd.105.009134
M3 - Article
C2 - 16581944
AN - SCOPUS:33745255092
SN - 0090-9556
VL - 34
SP - 1090
EP - 1095
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 7
ER -